VEXRX | WSMCX | VEXRX / WSMCX | |
Total Expense Ratio | 0.34 | 2.03 | 17% |
Annual Report Gross Expense Ratio | 0.34 | 2.09 | 16% |
Fund Existence | 23 years | 21 years | - |
Gain YTD | -14.722 | -16.781 | 88% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 50000 | 1000 | 5,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 19.8B | 466M | 4,249% |
Annual Yield % from dividends | 0.56 | 0.00 | - |
Returns for 1 year | -12.82 | -31.00 | 41% |
Returns for 3 years | -9.40 | -41.56 | 23% |
Returns for 5 years | 15.80 | -61.81 | -26% |
Returns for 10 years | -1.76 | -67.43 | 3% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XBI | 79.10 | 1.46 | +1.88% |
SPDR® S&P Biotech ETF | |||
CHI | 9.78 | 0.17 | +1.77% |
Calamos Convertible Opportunities and Income Fund | |||
SBIO | 28.02 | 0.45 | +1.63% |
ALPS Medical Breakthroughs ETF | |||
BCDF | 28.54 | 0.12 | +0.44% |
Horizon Kinetics Blockchain Dev ETF | |||
FEP | 41.67 | -0.06 | -0.14% |
First Trust Europe AlphaDEX® ETF |